Last $9.02 USD
Change Today +0.28 / 3.20%
Volume 22.4K
GNCA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

genocea biosciences inc (GNCA) Snapshot

Open
$8.34
Previous Close
$8.74
Day High
$9.21
Day Low
$8.34
52 Week High
03/10/14 - $23.99
52 Week Low
10/10/14 - $7.00
Market Cap
157.0M
Average Volume 10 Days
13.4K
EPS TTM
--
Shares Outstanding
17.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOCEA BIOSCIENCES INC (GNCA)

Related News

No related news articles were found.

genocea biosciences inc (GNCA) Related Businessweek News

No Related Businessweek News Found

genocea biosciences inc (GNCA) Details

Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. It uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines that act through T cell immune responses. The company is developing its lead product candidate, GEN-003, a therapeutic vaccine or an immunotherapy that is in Phase I/IIa trial to treat people with herpes simplex virus-2 (HSV-2) infections. It is also developing GEN-004, a vaccine candidate, which is in Phase I trial to prevent infections caused by pneumococcus; GEN-001 that is in pre-clinical stage for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of HSV-2 prophylaxis; and GEN-005 that is in research stage for treating malaria prophylaxis. The company was founded in 2006 and is based in Cambridge, Massachusetts.

44 Employees
Last Reported Date: 03/21/14
Founded in 2006

genocea biosciences inc (GNCA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $334.3K
Chief Medical Officer
Total Annual Compensation: $331.5K
Senior Vice President of Research
Total Annual Compensation: $238.3K
Vice President of Biopharmaceutical Developme...
Total Annual Compensation: $257.3K
Compensation as of Fiscal Year 2013.

genocea biosciences inc (GNCA) Key Developments

Genocea Biosciences, Inc. Presents Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek

Genocea Biosciences, Inc. announced the presentation of final data from the Phase 1/2a study of GEN-003, the company's immunotherapy candidate for treatment of genital herpes. The oral presentation, titled "Therapeutic HSV-2 Vaccine (GEN-003) Results in Durable Reduction in Genital Lesions at 1 Year ", will be given on Oct. 11 at IDWeek 2014(TM) in Philadelphia. The Phase 1/2a clinical trial was a double-blind, placebo-controlled, dose-escalation study to evaluate the safety and immunogenicity of GEN-003. In addition, the study was designed to demonstrate proof-of-concept that GEN-003 can reduce HSV-2 viral shedding, a measure of viral activity, and the genital lesion rate, the percentage of days during which the subjects experienced visible herpes outbreaks or lesions. Current HSV-2 therapies only partially control clinical symptoms and viral shedding, which drives disease transmission. During a 28 day observation period 6 months after GEN-003 dosing, subjects who received 30 microgram doses of GEN-003 had a 65% reduction in genital lesion rates compared to baseline (p<0.001). In addition, during that same period, those subjects experienced a 40% reduction in viral shedding compared to baseline (p<0.001). Twelve months after the final dose, the mean reduction in the genital lesion rate was 42% below baseline for this dose group. Immune responses to the treatment, including T cell, IgG, and neutralizing antibody, remained significantly above baseline at the end of the 12 month follow up. The study enrolled 143 subjects with a history of moderate-to-severe recurrent HSV-2 infection at seven clinics in the United States. Patients were sequentially enrolled into one of three dose cohorts (10, 30 or 100 micrograms of each vaccine antigen combined with 50 micrograms of Matrix M adjuvant) and randomized within cohorts to receive either GEN-003, vaccine antigens without adjuvant or placebo. Patients were given three injections of the assigned treatment into an arm muscle at 21 day intervals. Safety, antibody, and T cell responses to GEN-003 were followed and measured for 12 months after the last dose.

Kenneth Bate Joins the Board of Directors of Genocea Biosciences

Genocea Biosciences reported that Kenneth Bate has joined the company's board of directors. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee. Bate is currently is chairman of the board of Cubist Pharmaceuticals, and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and Catabasis Pharmaceuticals. Bate previously served as president and chief executive officer of Archemix Corp. and NitroMed, chief financial officer of Millennium Pharmaceuticals and Biogen and co-founded JSB Partners.

Genocea Appoints Kenneth Bate to its Board of Directors

Genocea Biosciences reported that Kenneth Bate has joined the company's board of directors. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee. Bate is currently chairman of the board of Cubist Pharmaceuticals, and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and Catabasis Pharmaceuticals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNCA:US $9.02 USD +0.28

GNCA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $2.85 USD -0.03
Eurocine Vaccines AB kr11.80 SEK -0.20
GenVec Inc $1.75 USD +0.03
Progenics Pharmaceuticals Inc $4.70 USD -0.10
ZIOPHARM Oncology Inc $2.55 USD +0.08
View Industry Companies
 

Industry Analysis

GNCA

Industry Average

Valuation GNCA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 623.9x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 342.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOCEA BIOSCIENCES INC, please visit www.genocea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.